Believe what you like. Odds are that primary/secondary were missed. Revision of SAP to telephone directory proportions seems to lead to that conclusion. Top line results will not be undeniable. Probably raise more questions than answers. Adds to uncertainty and whether approval anytime soon. Highly toxic financing looming and R/S not too far off. The market knows something. New lows coming soon. JMHO
There’s a simpler explanation for the decline in the share price . . . Volume is the key.
Well, yeah. You just proved Umibe's point. There is no volume because this is a failed trial that is now 12 years old with no end in sight. If this company was truly on the verge of releasing game-changing results for the treatment of cancer, do you really think this stock would be trading under $200K per day and the share price would have lost 40 percent of its value since ASCO? There are a lot of really smart people who have been watching this company for a long time, and none of them are buying. That's because they know what is coming. They are also capable of asking simple questions, such as:
- If this trial had met its primary indicator target then why didn't they announce it years ago when the pfs threshold was met?
Everyone who tries to answer that question ends up twisting themselves into a logical pretzel, because there's really only one answer and everybody knows it: the trial did not meet its primary indicator. That's why they dropped PFS like a hot potato. That's why they suddenly changed direction and started talking about long tails. There's one thing I would be willing to bet my house on: if this trial had met its primary indicator we would 100-percent guaranteed without question know about it. I can promise you that. Those who argue otherwise are either not very smart people, or, while they may know a lot of biotechnology minutiae, they don't understand the first thing about business.
News 
Market Data 
Discover 
AI
